Innate lymphoid cells – the European quest for innovative cancer prognosis and immunotherapy
ILCquest is a pan-European COST Action dedicated to advancing the understanding of innate lymphoid cells (ILCs) and their role in cancer prognosis, immune regulation, and immunotherapy.
By bringing together clinicians, immunologists, cancer biologists, and data scientists, the Action aims to bridge fundamental research and clinical application, fostering innovative strategies for cancer diagnosis, patient stratification, and treatment.
• Strengthening European collaboration on ILC research
• Attaining uniformed methodology and terminology across laboratories
• Promoting translation of ILC biology into clinical oncology and immunotherapy
• Supporting early-career researchers through training, networking, and mobility
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
